Identification and determination of phase I metabolites of propafenone in rat liver perfusate

被引:17
作者
Tan, WW [1 ]
Li, QM [1 ]
McKay, G [1 ]
Semple, HA [1 ]
机构
[1] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK S7N 5C9, Canada
基金
英国医学研究理事会;
关键词
propafenone; drug metabolism; HPLC; mass spectrometry; perfused rat liver;
D O I
10.1016/S0731-7085(97)00055-1
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Propafenone (PF) is a class IC antiarrhythmic agent. To study the mechanisms of PF interactions with dietary nutrients in isolated, perfused rat livers, metabolites of PF in liver perfusate were identified and an analytical method was developed for these metabolites plus parent drug. Identification of phase I metabolites was performed using HPLC/MS equipped with a Lichrospher RP-18 column and tandem mass spectrometry (MS/MS) with electrospray and atmospheric pressure chemical ionizations. Three major metabolite peaks, whose protonated molecular ions were m/z 358, 358 and 300, were identified as a propafenone derivative hydroxylated in the omega-phenyl ring (omega-OK-PF): 5-hydroxypropafenone (5-OH-PF), and N-despropylpropafenone (N-des-PF). The levels of omega-OH-PF, 5-OH-PF, N-des-PF and PF were determined simultaneously by HPLC with UV detection at 210 nm and a mobile phase of 0.03% triethylamine and 0.05% phosphoric acid in water-acetonitrile-methanol (45:20:35, v/v/v) after extraction with 5 ml diethyl ether at pH 10.0 and evaporation of solvent under nitrogen. The results revealed that omega-OH-PF, which was not found in humans, was the major metabolite of PF in rat liver perfusate, not 5-OH-PF which is the major metabolite in human plasma. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:991 / 1003
页数:13
相关论文
共 16 条
[1]   FOOD INCREASES THE BIOAVAILABILITY OF PROPAFENONE [J].
AXELSON, JE ;
CHAN, GLY ;
KIRSTEN, EB ;
MASON, WD ;
LANMAN, RC ;
KERR, CR .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 23 (06) :735-741
[2]  
BRUNNER F, 1989, ARZNEIMITTELFORSCH, V39-2, P1430
[3]   PROPAFENONE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN THE TREATMENT OF ARRHYTHMIAS [J].
HARRON, WG ;
BROGDEN, RN .
DRUGS, 1987, 34 (06) :617-647
[4]  
HEGE HG, 1986, ARZNEIMITTEL-FORSCH, V36-1, P467
[5]   THE METABOLIC-FATE OF H-2-LABELED PROPAFENONE IN MAN [J].
HEGE, HG ;
HOLLMANN, M ;
KAUMEIER, S ;
LIETZ, H .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1984, 9 (01) :41-55
[6]  
HEGE HG, 1984, ARZNEIM FORSCH DRUG, V39, P972
[7]   METABOLITE CUMULATION DURING CHRONIC PROPAFENONE DOSING IN ARRHYTHMIA [J].
KATES, RE ;
YEE, YG ;
WINKLE, RA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (06) :610-614
[8]   INVITRO CHARACTERIZATION OF THE HUMAN CYTOCHROME-P-450 INVOLVED IN POLYMORPHIC OXIDATION OF PROPAFENONE [J].
KROEMER, HK ;
MIKUS, G ;
KRONBACH, T ;
MEYER, UA ;
EICHELBAUM, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (01) :28-33
[9]  
LOW LK, 1991, WILSON GISVOLDS TXB, P45
[10]  
MASUBUCHI Y, 1993, DRUG METAB DISPOS, V21, P1012